BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)BALA CYNWYD, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome CaregiversBOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Folia Health announces the launch of Burden and Real-world Assessment of Caregiver Voice and Experiences in Prader-Willi syndrome (BRAVE-PWS), a fully remote observational study, sponsored by Soleno Therapeutics (
NASDAQ: SLNO), designed to better understand the real-world experience of caregivers supporting individuals with Prader-Willi syndrome (PWS). The study will use Folia’s app-based platform to collect Home-Reported Outcomes (HROs) and longitudinal caregiver-reported data over six months, helping researchers characterize the day-to-day experience associated with PWS and identify the factors that most affect caregiver well-being and household functioning.
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineNEW YORK and NEW ORLEANS, April 14, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (
NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive.
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (
NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNONEW ORLEANS, April 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO), if they purchased or otherwise acquired the Company’s shares between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineNEW YORK and NEW ORLEANS, April 07, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNONEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (
NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Commercial Viability Risks: Levi & KorsinskyLevi & Korsinsky, LLP alerts investors in Soleno Therapeutics, Inc. (
NASDAQ: SLNO) of a pending securities class action. Class Period: March 26, 2025 through November 4, 2025. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (
NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)BALA CYNWYD, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (
NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SLNO Stock Alert: Halper Sadeh LLC is Investigating Whether Soleno Therapeutics, Inc. is Obtaining a Fair Price for its ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating the sale of Soleno Therapeutics, Inc. (
NASDAQ: SLNO) to Neurocrine Biosciences for $53.00 per share in cash.
SLNO Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages SLNO Investors With Losses to Contact the FirmSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNONEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (
NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2026 lead plaintiff deadline.
